ArticleChinese medicine2026
Exploring the mechanism of Qinlian Yuyang Decoction in the treatment of ulcerative colitis based on multi-omics technology.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Isorhamnetin ameliorates active ulcerative colitis potentially involving the Nrf2-PTGS2 axis: an integrative study from clinical evidence mining to in vivo validation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe global incidence of ulcerative colitis (UC) is increasing, yet effective clinical treatment options remain limited. Qinlian Yuyang Decoction (QYD), a modified formulation based on Gegen Qinlian Decoction (GQD), has been optimized to better alleviate the pathological characteristics of UC. Although QYD is considered potentially more suitable for UC treatment, its potential mechanism of action is still unclear. PURPOSE: To explore the mechanism of QYD in the treatment of UC based on multi-omics.
methodThe therapeutic effects of QYD for UC were evaluated using the dextran sulfate sodium (DSS)-induced UC mice model. Then, 16S rRNA sequencing and untargeted metabolomics were employed to identify key microbiota and metabolites regulating the intestinal microenvironment. Furthermore, proteomic analysis was carried out to elucidate the underlying mechanisms mediated by the key metabolites.
resultsQYD alleviated physiochemical indices in UC mice, including weight loss, diarrhea, and bloody stools, resulting in lower Disease Activity Index (DAI) scores. It also suppressed inflammatory and intestinal barrier disruption in colonic tissues. Integrated metabolomic and 16S rRNA analyses demonstrated that the therapeutic effects of QYD on UC are mediated through enrichment of gut commensal D. longicatena and increasing tyrosine levels. Oral treatment of live D. longicatena considerably ameliorates colitis symptoms in UC mice. Tyrosine has similar protective effects against UC. Our investigation using quantitative proteomics to elucidate the mechanism of tyrosine in UC revealed that tyrosine suppresses inflammatory signaling pathways, modulates immune responses, and inhibits vascular endothelial cell migration and proliferation in the UC model-effects consistent with those of QYD. In summary, our findings indicate that QYD alleviates UC by elevating gut levels of the commensal bacterium D. longicatena and tyrosine, thereby suppressing inflammatory and immune responses while protecting the intestinal barrier. These results identify novel therapeutic targets and provide fresh perspectives for UC treatment.
conclusionThese findings suggest that Dorea longicatena and tyrosine play indispensable roles in the therapeutic mechanism of QYD against UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.